SCTX

12.1608.02%
SL

Svetlana Lucas

Independent Director

Dr. Svetlana Lucas, Ph.D., is Independent Director of Jasper Therapeutics, Inc. from June 18, 2024. She serves as Chief Operating Officer of Scribe Therapeutics Inc. since September 2026 and served as its Chief Business Officer since June 2019 until September 2026 and had been its Chief Operating Officer since July 2026. Dr. Lucas serves as an Independent Director of aTyr Pharma, Inc. since June 2019. She serves as Advisor at Radar Therapeutics Inc. Dr. Lucas serves as a Chief Business Officer at a newly formed biotechnology company. Dr. Lucas served as Senior Vice President of Business Development at Tizona Therapeutics, Inc. Before joining Tizona, Dr. Lucas was Head of Oncology and Inflammation External Research and Development at Amgen Inc. from August 2014 to July 2015, where she oversaw business development activities, including Amgen’s strategic cancer immunotherapy research collaboration and licensing agreement with Kite Pharma and collaborated with Amgen Ventures on several investments in oncology and inflammation. Dr. Lucas joined Amgen following the acquisition of Onyx Pharmaceuticals, Inc., where she spearheaded the company’s oncology partnering strategy and due diligence of new opportunities. Prior to Onyx, she held positions of increasing responsibility in strategy, business development and strategic marketing at Amgen, PDL BioPharma/Facet Biotech and XOMA Corporation. Dr. Lucas began her career as a strategy consultant in the Life Sciences practice of McKinsey & Company, Inc. Dr. Lucas received her Ph.D. in Molecular Biology and Biochemistry from California Institute of Technology and an undergraduate degree in Biology from Moscow State University.

Positions